The FDA is facing scrutiny regarding mifepristone safety after study findings prompted the Trump administration to launch an investigation into drug safety.

13 reports, 3 independent Updated Oct 8

Gone quiet

Reports: 13
Developments: 1
Repetition: 92%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Well supportedReported by 3 independent outlets

The FDA is facing scrutiny regarding mifepristone safety after study findings prompted the Trump administration to launch an investigation into drug safety.

Who's involved

What this event is mainly about

FDA Donald Trump

Keep exploring

Part of

The FDA is currently reviewing concerns regarding mail-order abortion pills and the circulation of mifepristone. All 1 developments

The entities involved

FDA
- The FDA approved Miplyffa for the treatment of Niemann-Pick disease.00:55
- iRhythm Technologies launched its Zio ECG system in Japan following FDA clearance, amid reports that Trump-era tariffs benefit AI stocks.Fri 23:50
Donald Trump
American businessman and politician (born 1946), President of the United States (2017–2021; since 2025)
- NPR investigated a detention plan implemented by the Trump administration, involving DHS policy officials.01:29
- Trade deals were announced between Donald Trump and Gulf States, alongside renewed clashes between the US and Iran and inflation data guiding Fed policy.01:27

Coverage

Newest first; wire copies grouped

Oct 8talkingpointsmemo.com
Jul 24wkzo.comUS judge says Biden-era restrictions on prescribing abortion drug are unlawful
Jul 13dailysignal.com

10 more outlets ran the same wire story